FDA Names First AI Deputy Commissioner and Stabilizes Center Leadership
HHS appoints permanent directors to key FDA centers and creates a new executive role to lead agency-wide AI strategy.
The U.S. Department of Health and Human Services (HHS) announced the appointment of four senior leaders at the Food and Drug Administration (FDA) on September 8, 2026. The move introduces a new executive role dedicated to artificial intelligence and stabilizes leadership across three of the agency's primary regulatory centers.
Among the most significant changes is the appointment of Jared Seehafer, M.S., as the FDA's first-ever Deputy Commissioner for Technology and Artificial Intelligence. Seehafer is tasked with leading the agency-wide strategy for software, technology, and AI. Additionally, the HHS named three acting directors to permanent positions: Michael Davis, M.D., Ph.D., will lead the Center for Drug Evaluation and Research (CDER); Karim Mikhail, B.Pharm, MSc, will head the Center for Biologics Evaluation and Research (CBER); and Bret Koplow, Ph.D., J.D., will direct the Center for Tobacco Products (CTP).
Modernization and Reform
These appointments align with a broader strategy by the Trump Administration and HHS to modernize federal technology and accelerate AI innovation. The administration aims to reform the FDA's regulatory frameworks to strengthen national health security and increase the availability of affordable medicines. According to HHS Secretary Robert F. Kennedy, Jr., the goal is to build an FDA that "moves faster, demands excellence, and delivers results for the American people."
Industry Implications
The creation of a dedicated Deputy Commissioner for AI signals a structural shift in how the FDA intends to integrate emerging technologies into its regulatory processes. By moving from acting to permanent leadership in CDER and CBER, the agency provides stability in the two centers most critical for drug and biologic approvals. This transition is viewed as essential for long-term policy implementation and providing the predictability that pharmaceutical and biotech industries require for development pipelines.
The Path Forward
FDA Acting Commissioner Kyle Diamantas, J.D., stated that these selections "signal the direction we are heading," suggesting that the new leadership structure is a precursor to further agency-wide shifts. Observers will now look to Seehafer's office to define the specific guidelines for AI-driven medical software and how the permanent directors at CDER and CBER will implement the administration's goals for affordable medicine and regulatory reform. This structural realignment suggests a pivot toward a more tech-centric regulatory approach, potentially shortening the distance between AI innovation and clinical application.